Advaxis, Inc. (NASDAQ:ADXS)’s stock price gapped down before the market opened on Wednesday . The stock had previously closed at $0.55, but opened at $0.58. Advaxis shares last traded at $0.59, with a volume of 169,259 shares.
Separately, Zacks Investment Research lowered Advaxis from a “buy” rating to a “hold” rating in a research note on Wednesday, October 30th.
The company has a market cap of $9.93 million, a P/E ratio of -0.03 and a beta of 3.43. The stock has a 50-day moving average of $0.37 and a 200 day moving average of $1.03.
Advaxis (NASDAQ:ADXS) last posted its quarterly earnings data on Monday, September 9th. The biotechnology company reported ($1.00) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.24) by $0.24. The business had revenue of $0.01 million during the quarter. Advaxis had a negative net margin of 113.67% and a negative return on equity of 67.08%. As a group, analysts forecast that Advaxis, Inc. will post -2.7 EPS for the current fiscal year.
Several large investors have recently modified their holdings of ADXS. JPMorgan Chase & Co. lifted its holdings in shares of Advaxis by 53,633.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 51,047 shares of the biotechnology company’s stock worth $107,000 after acquiring an additional 50,952 shares during the period. Renaissance Technologies LLC boosted its position in shares of Advaxis by 143.7% during the 2nd quarter. Renaissance Technologies LLC now owns 501,000 shares of the biotechnology company’s stock worth $1,047,000 after acquiring an additional 295,444 shares in the last quarter. Vanguard Group Inc. increased its stake in Advaxis by 71.1% in the second quarter. Vanguard Group Inc. now owns 230,106 shares of the biotechnology company’s stock valued at $481,000 after acquiring an additional 95,607 shares during the last quarter. Finally, Sabby Management LLC increased its stake in Advaxis by 3,547.9% in the third quarter. Sabby Management LLC now owns 1,521,982 shares of the biotechnology company’s stock valued at $403,000 after acquiring an additional 1,480,260 shares during the last quarter. Institutional investors own 30.33% of the company’s stock.
About Advaxis (NASDAQ:ADXS)
Advaxis, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer.
See Also: Management Fee
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.